|
1.
Share Success: Letters From Readers
Letter I: From Linda KP.
Received
at Testimonial Submit Form Mon, 25 Feb 2019 11:28:39 PST
(Unedited)
Hi My Name Is Linda. I Have An Incredible Story To Tell ABOUT MY RECENT ENCOUNTER WITH CANCER.
I have been taking 3 tsp. of EZorb Calcium every day since February in 2005 and added 2 Marvlix capsules after they were release in July of 2007.
Then on September 13, 2017 I was diagnosed by mammogram, sonogram and biopsy with Triple Negative Stage 1, Grade 3 aggressively growing Breast Cancer. The tumor measured at its largest dimension was 1.2 cm.
As soon as I got home from the clinic I broke the news to my husband and he told me to up the Marvlix to the cancer dosage of 10 capsules a day. He said "cancer is not something to play around with, we are calling MD Anderson Cancer Center " (rated #1 in USA).
I met with the team of doctors at MD Anderson Cancer Center in October 2017. They wanted a lot of information, number of family members with cancer, list of all medication I was taking including supplements.
My husband explained to the doctors that Marvlix was 100% Cordyceps Sinensis extract and I have been taking the cancer dosage since September 13.
You could tell by the look on their faces that they had never heard of Marvlix. After several meetings with different doctors they recommended surgery, chemotherapy, and radiation. I was told to stop all medications except blood pressure medication prior to surgery on November 14, 2017. I read several Medical Studies on Cancer and taking Marvlix which said it may reduce the size of the tumor and in some cases it could even disappear.
Since I was originally taking Marvlix to help control my blood pressure and cholesterol, which it did, I considered it blood pressure medication and kept on taking it every day up until surgery hoping it would keep my tumor from growing or metastasizing (spreading).
About a week after the surgery my surgeon called me at home at night to tell me she had gotten the lab report back on the tumor she removed. To my surprise and extreme joy, my surgeon stated that the tumor had not spread but it had shrunk to just .7 cm, a 42% decrease in size.
She became interested in Marvlix and asked if I could bring her more information on my next visit to MD Anderson.
On December 1st, she said because of the change in size, no cancer in lymph nodes or margins of breast tissue, she saw no need to start chemotherapy and recommended going straight to radiation therapy as a precaution to insure no cancer cells were left behind.
I am sure this is due to effects of my cancer treating dose of 10 Marvlix per day, All cancer patients are instructed to exercise, eat very healthy, have many to pray for them, and the only difference with me was the Marvlix.
The first day of radiation treatment they explained to our group about side effects:
1st week no side effects, going into 2nd week feeling fatigue and weakness, 3rd week pinkness of breast like mild sunburn and some may, due to weakness, need assistance in walking, 4th week bad sunburn with blistering. I continued to take 10 Marvlix per day throughout radiation since it was for my BP. I was the only woman in my group who had no side affects, NONE. My energy levels were high and I continued walking 4 to 5 miles a day the entire time.
Going into my 3rd week of radiation the scheduling person thought I was going to be there for 1 extra week leaving no option but double up my radiation on the 4th week. I was also to have a stress test before starting radiation that was overlooked so they had to
squeeze that in too, I completed the whole test with no problems. The cardiologist was really pleased. We left MD Anderson for a 9 hour drive home getting there close to midnight on a Friday, after being gone a month. With just Saturday and Sunday off , I was back to work on Monday teaching 5 classes. Many of my colleagues wanted to know what in the world I was doing back to work so soon, and I just smiled.
It's now April 2018 and I just got back from MD Anderson after my 1st checkup. I had to do a DEXA scan (Bone Mineral Density Test). My oncologist said I have a little thinning of my bones, and to keep taking my calcium.
You bet I will and just what do you expect for a person going on 69, 22 year old bones?
When I got the DEXA scan report from MD Anderson, the little thinning was a T-score -0.9! EZorb is the best calcium compound in the world but not the fountain of youth.
I had to go back to MD Anderson for my 2nd checkup on July 19, 2018. The checkup went so well that instead of checkups every 3 months, I only go every 6 months. So we will see how I have progressed in January 2019. I will have to go back for checkups every six months for 5 years or until they release me as cancer free. I will also be taking the Marvlix 10 capsules per day for that same period.
I am not a person that writes about personal experiences and publishes them for the whole world to read. When you have had Cancer it is a wakeup call like you have never experienced before so I hope and pray that many will read this and if it only helps 1 person it was well worth it.
Linda KP
***************************************************
From
the Desk of EZorb Newsletter Editor:
This
newsletter is now read by over 120,000 subscribers
worldwide. Success stories you have contributed over
the years have had a great impact on many people's
quality of life. Your continuous support will be
greatly appreciated by tens of thousands who have been
suffering and would continuously suffer, without your
help! Please email your
story to sharesuccess @ ezorbonline.com
or simply post it at Testimonial
Submit Form. Your personal information will never be
revealed to the public. We appreciate your effort.
2.
Research News: Artificial Intelligence May Help Diagnosis of Early Glaucoma
A deep learning classifier model developed to diagnose early glaucoma is significantly more accurate than other machine learning methods, Japanese researchers report.
Ryo Asaoka (University of Tokyo, Japan) and team used optical coherence tomography (OCT) measurements, obtained with the RS 3000 OCT machine, to create the tool. It was initially pre-trained using 4316 OCT images from 193 healthy eyes and 1565 eyes with open angle glaucoma (OAG).
The researchers explain that pre-training is important because deep learning requires a large dataset to achieve an accurate diagnosis, but heterogeneity among OCT machines from different manufacturers, and among different versions of the same machine, make it difficult to collect the amount of data needed.
They therefore used "transfer learning" to build the initial deep learning model with the pre-training dataset then further trained the model with images from 84 normal eyes and from 94 eyes with early OAG, taken with a different OCT instrument (OCT-1000 or OCT-2000).
"Transfer learning is a popular approach in [deep learning] where a model developed for a somewhat different task is then reused as the starting point for a model on a second separate task. In other words, the performance of a [deep learning] model can be vastly improved by conducting a preliminary training phase using a different large dataset," Asaoka and co-authors remark.
Finally, the model was tested by inputting the 8x8 grid macular retinal nerve fiber layer thickness and ganglion cell complex layer thickness from OCT-1000 or OCT-2000 images from 114 eyes of patients with early OAG and from 82 normal eyes.
The investigators report in the American Journal of Ophthalmology that the area under the receiver operating characteristic curve (AUC) for the final deep learning model for diagnosing glaucoma was 93.7%.
This was significantly higher than when the deep learning classifier was constructed without the pre-training process (78.8%), was pre-trained but not further trained (76.6%) or it was pre-trained and trained simultaneously (78.2%).
The AUC for the classifier was also significantly larger than those achieved with other machine learning methods built using the same datasets as the deep learning model, namely random forests (RF; 82.0%) and support vector machine (SVM; 67.4%).
Sensitivity and specificity were also higher with the deep learning classifier, at 82.5% and 93.9%, respectively, than with RF (64.0% and 89.0%, respectively) and SVM (64.0% and 89.0%, respectively).
Asaoka et al conclude that their model "has a high diagnostic ability and may be useful to support clinicians identify early-onset glaucoma."
Original article was published in 10-18-2018 | Ophthalmology | News | Article
3.
Useful Links
Frequently
Asked Questions & Answers
EZorb
Clinical Studies
Marvlix
Benefits
Order
Now
4.
Calcium
Absorption Test
EZorb
Calcium has set a new world record of absorption rate.
You can compare EZorb with other calcium supplements
by using the simple step-by-step instructions we
provide. E-mail your request to test @ elixirindustry.com
for a copy of the instructions.
5.
What Are Others Saying About EZorb and Marvlix?
EZorb and Marvlix have restored confidence in thousands of men
and women. It has brought happiness and healthy life
to families around the world. Click here
to read what people say about EZorb and Marvlix. |
